Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor

Sharouni, Mary Ann El; Stodell, Matthew; Ahmed, Tasnia; Suijkerbuijk, Karijn P M; Cust, Anne E.; Witkamp, Arjen J.; Sigurdsson, V.; Diest, Paul J. van; Scolyer, Richard A.; Thompson, John F.; Gils, Carla H. van; Lo, Serigne

doi:10.1016/j.annonc.2020.11.015

Cited by 31 publications

(54 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…El Sharouni and colleagues examined the improvement in staging accuracy and prognostic information when knowledge of the pathological status of the SLN was added to primary tumor clinicopathological features. 14 The study further corroborated a large body of investigation that SLN pathological status is an independent predictor of clinical outcomes for these patients and that optimal modeling requires knowledge of the pathological status of the SLN. Their well-conducted analysis included clinicopathological and follow-up data from two datasets comprised of approximately 15 000 patients from different parts of the world, which supported a robust platform for prognostic model development and validation.…”

supporting

confidence: 69%

Sentinel node biopsy for primary cutaneous melanoma

2021

View full text Add to dashboard Cite

supporting

confidence: 69%

Sentinel node biopsy for primary cutaneous melanoma

2021

View full text Add to dashboard Cite

“…However, a positive SLNB improves the prediction of melanoma mortality marginally (C-statistic only 3%) beyond that of established clinical and pathologic criteria [10]. Currently any role for SLNB is unclear, but the complications of nodal biopsy and clearance are established and may cause permanent impairment.…”

Section: Key Pointsmentioning

confidence: 99%

Ethical Challenges in Delivering Surgical Innovation: Laparoscopic Bariatric-Metabolic Surgery and Sentinel Node Biopsy for Melanoma: an Australian Perspective

Dixon

Anderson²,

Hamdorf

2023

OBES SURG

View full text Add to dashboard Cite

The Australian public must have confidence that innovative surgical interventions are safe, effective, and justifiable economically. Surgical innovation involves risks. Informed consent is challenging when the risk to benefit ratio is unknown, and especially so when the objectivity of the surgeon-innovators, colleagues, universities, and hospitals is compromised by conflict of interest. The primary areas of conflict for those involved in surgical innovation are economic, but prestige, career advancement, optimism bias, and reputation for being at the cutting edge are all at play [1]. By its nature, innovation in surgery usually precedes a full evaluation of key health outcomes. Two examples of surgical innovation from the 1990s are contrasted.Society's narratives regarding the management of cancer and obesity are strikingly different. Cancer is discussed positively reflecting hope and optimism. There is positive engagement from the health sector, and advocacy groups and forums provide patient support and advice. Cancer therapy is discussed alongside health outcomes and survival. In * John B Dixon

show abstract

“…Drug resistance is an important characteristic of melanoma, resulting in the lack of effectiveness of current drug treatments [17][18][19][20][21]. Surgery [22,23], chemotherapy [24,25], and immunotherapy [26,27] are the most commonly approaches. However, these treatments are largely limited by an advanced cancer diagnosis, off-target drug delivery and concentration, systemic toxicity, and drug-induced undesirable side effects.…”

Section: Introductionmentioning

confidence: 99%

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Song

Liu

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

show abstract

Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor

Cited by 31 publications

References 34 publications

Sentinel node biopsy for primary cutaneous melanoma

Sentinel node biopsy for primary cutaneous melanoma

Ethical Challenges in Delivering Surgical Innovation: Laparoscopic Bariatric-Metabolic Surgery and Sentinel Node Biopsy for Melanoma: an Australian Perspective

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Contact Info

Product

Resources

About